Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
KCNQ4 CRISPR/Cas9 KO Plasmid (h): sc-403090
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- KCNQ4 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the KCNQ4 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: KCNQ4 Antibody (F-10): sc-271320
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
KCNQ4 CRISPR/Cas9 KO Plasmid (h) | sc-403090 | 20 µg | $397.00 |
Overview
KCNQ4 encodes a voltage-gated potassium channel subunit (Kv7.4) that contributes to the M-current and stabilizes membrane potential by regulating K⁺ efflux in excitable cells. Channel activity shapes action potential firing, cellular excitability, and calcium-dependent signaling through control of resting potential and repolarization dynamics. KCNQ4 is prominently linked to auditory physiology, where altered channel function perturbs ionic homeostasis and excitability in cochlear hair cells and associated circuits. Genetic variation or dysregulation of KCNQ4 has been associated with hereditary hearing impairment, making it a relevant target for mechanistic studies of sensory transduction and neuronal signaling pathways.
KCNQ4 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the KCNQ4 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the KCNQ4 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the KCNQ4 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish KCNQ4 protein expression.
This CRISPR knockout system enables efficient generation of KCNQ4-deficient cell models for investigation of KCNQ4 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting KCNQ4 exon(s) critical for KCNQ4 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple KCNQ4 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by KCNQ4 CRISPR/Cas9 KO Plasmid (h) and KCNQ4 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the KCNQ4 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by KCNQ4 HDR Plasmid (h) and KCNQ4 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by KCNQ4 homology arms to support homology-directed repair at defined KCNQ4 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.